TrialCancer2019

Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (

Scott T Tagawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.